Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laila M Poisson

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Nature Genetics|April 25, 2018
Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastomaAna C deCarvalho, Hoon Kim, Laila M Poisson, et al.
NPJ Precision Oncology|November 13, 2018
Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathwaysSameer H Halani, Safoora Yousefi, Jose Velazquez Vega, et al.
Neuro-Oncology|February 25, 2021
DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological featuresMaritza S Mosella, Thais S Sabedot, Tiago C Silva, et al.
Neuro-Oncology|February 9, 2021
A serum-based DNA methylation assay provides accurate detection of gliomaThais S Sabedot, Tathiane M Malta, James Snyder, et al.
Nature|February 13, 2009
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionArun Sreekumar, Laila M Poisson, Thekkelnaycke M Rajendiran, et al.
European Urology|June 12, 2010
Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8Arun Sreekumar, Laila M Poisson, Thekkelnaycke M Rajendiran, et al.
AJNR. American Journal of Neuroradiology|April 29, 2024
Sex-Specific Differences in Patients with <i>IDH1</i>-Wild-Type Grade 4 Glioma in the ReSPOND ConsortiumSree Gongala, Jose A Garcia, Nisha Korakavi, et al.
Neuro-Oncology|February 25, 2022
Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumorsGrayson A Herrgott, Karam P Asmaro, Michael Wells, et al.
Neuroradiology|July 19, 2023
Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortiumMatthew D Lee, Sohil H Patel, Suyash Mohan, et al.
Neuro-Oncology|March 11, 2020
AI-based prognostic imaging biomarkers for precision neuro-oncology: the ReSPOND consortiumChristos Davatzikos, Jill S Barnholtz-Sloan, Spyridon Bakas, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Nature Genetics|April 25, 2018
Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastomaAna C deCarvalho, Hoon Kim, Laila M Poisson, et al.
NPJ Precision Oncology|November 13, 2018
Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathwaysSameer H Halani, Safoora Yousefi, Jose Velazquez Vega, et al.
Neuro-Oncology|February 25, 2021
DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological featuresMaritza S Mosella, Thais S Sabedot, Tiago C Silva, et al.
Neuro-Oncology|February 9, 2021
A serum-based DNA methylation assay provides accurate detection of gliomaThais S Sabedot, Tathiane M Malta, James Snyder, et al.
Nature|February 13, 2009
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionArun Sreekumar, Laila M Poisson, Thekkelnaycke M Rajendiran, et al.
European Urology|June 12, 2010
Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8Arun Sreekumar, Laila M Poisson, Thekkelnaycke M Rajendiran, et al.
AJNR. American Journal of Neuroradiology|April 29, 2024
Sex-Specific Differences in Patients with <i>IDH1</i>-Wild-Type Grade 4 Glioma in the ReSPOND ConsortiumSree Gongala, Jose A Garcia, Nisha Korakavi, et al.
Neuro-Oncology|February 25, 2022
Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumorsGrayson A Herrgott, Karam P Asmaro, Michael Wells, et al.
Neuroradiology|July 19, 2023
Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortiumMatthew D Lee, Sohil H Patel, Suyash Mohan, et al.
Neuro-Oncology|March 11, 2020
AI-based prognostic imaging biomarkers for precision neuro-oncology: the ReSPOND consortiumChristos Davatzikos, Jill S Barnholtz-Sloan, Spyridon Bakas, et al.
Pageof 7